Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Sleep and Stress in Opioid Use Disorder
NCT04287062Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sleep disorder comparing Placebo with Suvorexant (2 arms). Primary endpoints: Total Sleep Time at 28 days, Total Wake Time After Sleep Onset at 28 days and 1 more. Started Nov 2020; status: completed.
02
Drugs
suvorexant
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT04287062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287062.